Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.53 USD | -3.72% | +0.62% | -23.72% |
May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.72% | 2.12B | |
+9.47% | 114B | |
+11.57% | 104B | |
-13.79% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.61% | 17.89B | |
+7.48% | 14.28B | |
+35.98% | 12.55B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Rocket Pharmaceuticals Says Gene Therapy Candidate Received US FDA Fast Track, Orphan Drug Designations